Last updated: July 28, 2026
PRIMAXIN (imipenem/cilastatin) clinical trials update, market analysis, and exclusivity timeline
PRIMAXIN is a brand of imipenem and cilastatin for IV treatment of serious bacterial infections. The IP and trial landscape is dominated by the imipenem/cilastatin molecule’s long-established status and broad generic availability. Current commercial value is primarily a function of hospital formularies, tendering cycles, and substitution dynamics rather than new clinical-development milestones.
What is PRIMAXIN and what infections does it treat?
PRIMAXIN is an IV antibiotic combination of:
- Imipenem (carbapenem): broad-spectrum antibacterial activity, β-lactam.
- Cilastatin (renal dehydropeptidase inhibitor): prevents imipenem degradation and preserves renal active levels.
Typical labeled indications (set by FDA-approved labeling for the brand product):
- Serious intra-abdominal infections
- Lower respiratory tract infections
- Urinary tract infections
- Skin and skin structure infections
- Gynecologic infections
- Septicemia
- Off-label use in hospitals commonly tracks local susceptibility patterns and stewardship protocols.
Dose forms and administration constraints that affect adoption
- IV infusion dosing, typically q6h to q8h depending on renal function and infection severity (per labeling).
- Requires renal function monitoring due to cilastatin/imipenem renal handling.
- Stewardship and line-item stewardship restrictions can limit use to carbapenem-appropriate cases.
What is the latest clinical trials update for PRIMAXIN?
No current late-stage registration trials for PRIMAXIN as a standalone brand were identified in the publicly indexed trial record on the basis of the information available here. The clinical evidence base for imipenem/cilastatin is mature and historically anchored to:
- Older pivotal trials establishing efficacy across infection categories.
- Subsequent safety updates and labeling refinements.
- Ongoing stewardship and comparative effectiveness studies that generally evaluate imipenem/cilastatin versus other carbapenems or antibiotic classes, rather than testing PRIMAXIN as a new molecular entity.
What trial themes dominate for imipenem/cilastatin in 2023-2026?
Where studies appear in the public record, they most often focus on:
- Comparative outcomes versus other carbapenems (e.g., meropenem, ertapenem).
- Microbiologic eradication and resistance trends.
- PK/PD optimization in critically ill patients and renal impairment.
- Clinical outcomes in ESBL-producing Enterobacterales and mixed resistant flora settings.
Is PRIMAXIN still protected by patents or exclusivity?
PRIMAXIN is a legacy antibiotic. The practical exclusivity landscape for imipenem/cilastatin is characterized by:
- Expired or near-expired composition-of-matter coverage for the core molecule.
- Ongoing patenting, if any, typically shifts to formulation, manufacturing, or method-of-use refinements, but the market is already accessible to generics in the United States.
Orange Book status
Given the maturity of the active ingredient and widespread generic penetration, PRIMAXIN’s market access is generally not driven by current Orange Book exclusivities in the way it would be for a newer drug. If an Orange Book listing exists for a PRIMAXIN product configuration, it historically would list patents that have long since become irrelevant to first generic entry timing.
When does PRIMAXIN lose exclusivity and how soon can generics launch?
For legacy imipenem/cilastatin, the exclusivity and entry window is already past:
- Composition-of-matter exclusivity is not a limiting factor.
- Generic entry timing is primarily governed by:
- ANDA readiness
- facility and supply chain capability
- label equivalence (bioequivalence and performance)
- tender requirements and hospital formulary decisions
What patents protect imipenem/cilastatin (PRIMAXIN) and how many are still active?
Patent estates for imipenem/cilastatin typically show substantial historical filings but limited current impact on generic competition. Any remaining active patents, if present, are usually not molecule-blocking and often relate to:
- manufacturing processes
- specific formulation variants
- stability/packaging improvements
- narrow method-of-use claims (less common for widely substituted antibiotics)
What Paragraph IV challenges exist for PRIMAXIN?
No materially relevant, brand-blocking Paragraph IV litigation signals are expected for a legacy imipenem/cilastatin product where multiple generics have long been launched. In such cases, if FDA litigation occurs, it is usually between generic entrants and holders of remaining secondary patents, and disputes are less common at scale than for newer brands.
What is the FDA regulatory status of PRIMAXIN?
PRIMAXIN is an FDA-approved IV antibiotic under an approved NDA or branded equivalent product. In commercial practice:
- The active ingredient set is effectively “off-patent” for most business planning purposes.
- Regulatory reliance for generics is typically via ANDAs using bioequivalence and manufacturing controls.
Which companies market imipenem/cilastatin and how does competitive landscape affect PRIMAXIN?
The competitive set is structurally dominated by:
- Multiple generic manufacturers of imipenem/cilastatin IV
- Occasional supplier-specific availability issues
- Hospital contracting that prices to acquisition cost plus distribution margin
Market dynamic: brand performance is tied to pharmacy and procurement decisions rather than unique clinical superiority, since generics have equivalent active ingredients and broad clinical familiarity.
How does PRIMAXIN compare with meropenem, ertapenem, and other carbapenems?
Decision drivers used in hospitals and stewardship committees include:
- Spectrum of activity
- Dosing frequency and infusion burden
- Renal toxicity considerations
- Local susceptibility patterns
- Resistance pressure and guideline adherence
- Cost and formulary positioning
In most stewardship frameworks:
- Meropenem is often selected for broad serious infections.
- Ertapenem is often chosen for once-daily regimens when appropriate.
- Imipenem/cilastatin remains important where its spectrum or clinician familiarity aligns with guidelines and susceptibilities, but it faces cost pressure from generics.
Market analysis for PRIMAXIN: demand drivers, pricing pressure, and revenue exposure
Demand drivers
- High-acuity hospital settings: ICU, sepsis, complicated infections.
- Persistent burden of resistant gram-negative pathogens drives continued carbapenem use in appropriate cases.
- Stewardship guidelines increase monitoring but do not eliminate carbapenem demand.
Pricing pressure
- Generic substitution compresses pricing.
- Brand share shrinks as procurement awards generics unless:
- there are supplier disruptions
- tender agreements favor a brand
- specific hospital formularies maintain a preferred brand SKU
Revenue exposure
- Brand revenue is typically exposed to:
- contract renewals
- inventory coverage and supply reliability
- competitor pricing changes at rebid cycles
- shifts to alternative carbapenems (meropenem-based pathways) in susceptibility trends
Market projection for PRIMAXIN through 2030
For a legacy antibiotic with broad generic competition, projections generally follow:
- Flat to modest decline in brand share unless PRIMAXIN holds a durable preferred-contract status.
- Volume stability is possible if:
- clinicians continue to use imipenem/cilastatin for specific syndrome bundles
- regional resistance patterns support its continued selection
- Price declines and interchangeability effects remain primary downside drivers.
A reasonable business-planning posture is:
- Treat brand growth as constrained by generic competition.
- Focus forecasting on contract and supply stability rather than incremental clinical trial breakthroughs.
What commercialization risks exist for PRIMAXIN?
- Formulary substitution: brand displacement at tender.
- Supply chain fragility: temporary shortages can briefly lift preferred brand positioning, then revert.
- Antibiotic stewardship restrictions: increased criteria for carbapenem use may reduce unrestricted use.
- Competitor switching: shifts to other carbapenems or non-carbapenem regimens for ESBL infections (when susceptibility supports).
What manufacturing or IP barriers could delay generic competition for PRIMAXIN?
For imipenem/cilastatin, barriers are typically operational, not IP:
- Sterile manufacturing capacity and aseptic controls
- Stability and reconstitution performance in commercial packaging
- Scale economics and cost of raw materials
- Quality system compliance and batch release throughput
If any process IP remains, it rarely stops market entry at scale; it more often increases compliance and process validation overhead.
Key Takeaways
- PRIMAXIN is a legacy IV imipenem/cilastatin antibiotic; clinical development is not currently the main driver of business value.
- The competitive landscape is dominated by generics, so brand exclusivity is not the central forecasting variable.
- Market outcomes depend primarily on hospital procurement, stewardship-driven utilization patterns, and competitor switching among carbapenems.
- Near- to mid-term projections through 2030 are most consistent with flat-to-declining brand share under ongoing generic pricing pressure.
FAQs
- Does PRIMAXIN have newer clinical trials comparing it to newer anti-gram-negative therapies?
- Are carbapenem-resistant organism rates changing PRIMAXIN use in hospitals?
- What renal dosing adjustments are required for PRIMAXIN in chronic kidney disease?
- How do hospital formularies decide between imipenem/cilastatin and meropenem?
- What supply issues most often impact availability of imipenem/cilastatin IV products in the US?
References
- FDA. Drug Approval Packages: Imipenem and Cilastatin (and related branded/generic products). U.S. Food and Drug Administration.
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (imipenem/cilastatin search). U.S. Food and Drug Administration.
- ClinicalTrials.gov. Search results for imipenem/cilastatin and related entries. National Library of Medicine.
